Clindamycin Navamedic 150 mg/ ml Norge - norsk - Statens legemiddelverk

clindamycin navamedic 150 mg/ ml

navamedic asa - klindamycinfosfat - injeksjonsvæske/konsentrat til infusjonsvæske, oppløsning - 150 mg/ ml

Dalacin 150 mg/ ml Norge - norsk - Statens legemiddelverk

dalacin 150 mg/ ml

pfizer as - klindamycinfosfat - injeksjonsvæske, oppløsning - 150 mg/ ml

Dalacin 15 mg/ ml Norge - norsk - Statens legemiddelverk

dalacin 15 mg/ ml

pfizer as - klindamycinpalmitathydroklorid - granulat til mikstur, oppløsning - 15 mg/ ml

Dalacin 150 mg Norge - norsk - Statens legemiddelverk

dalacin 150 mg

pfizer as - klindamycinhydroklorid - kapsel, hard - 150 mg

Dalacin 300 mg Norge - norsk - Statens legemiddelverk

dalacin 300 mg

pfizer as - klindamycinhydroklorid - kapsel, hard - 300 mg

Alverin 18.7 mg/ g Norge - norsk - Statens legemiddelverk

alverin 18.7 mg/ g

zoetis finland oy - ivermektin - oralpasta - 18.7 mg/ g

Sabrilex 500 mg Norge - norsk - Statens legemiddelverk

sabrilex 500 mg

sanofi-aventis norge (3) - vigabatrin - tablett, filmdrasjert - 500 mg

Sabrilex 500 mg Norge - norsk - Statens legemiddelverk

sabrilex 500 mg

sanofi-aventis norge (3) - vigabatrin - granulat til mikstur, oppløsning - 500 mg

Comirnaty Den europeiske union - norsk - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.